These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 898167)

  • 21. Automated reading of Propidium Iodide lymphocytotoxicity tests for HLA-DR, MB, MT typing.
    Naipal AM; D'Amaro J; Bruning JW; van Leeuwen A; van Rood JJ
    Tissue Antigens; 1984 Nov; 24(5):302-6. PubMed ID: 6597977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of crossmatch outcome in highly sensitized dialysis patients based on the identification of serum HLA antibodies.
    Oldfather JW; Anderson CB; Phelan DL; Cross DE; Luger AM; Rodey GE
    Transplantation; 1986 Sep; 42(3):267-70. PubMed ID: 3529527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Luminex-based virtual crossmatching for renal transplantation in South Africa.
    Worsley CM; Mayne ES; Suchard MS
    S Afr Med J; 2011 Dec; 102(1):40-3. PubMed ID: 22273137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for two series of B-cell antigens in man and their comparison with HLA-D.
    van Rood JJ; van Leeuwen A; Keuning JJ; Termijtelen A
    Scand J Immunol; 1977; 6(5):373-84. PubMed ID: 70054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunofluorescence of HL-A antigens in kidney tissue.
    Sybesma JP; Kater L; Borst-Eilers E; de Planque BA; van Soelen T; Tuit G
    Proc Eur Dial Transplant Assoc; 1973; 10(0):406-11. PubMed ID: 4606644
    [No Abstract]   [Full Text] [Related]  

  • 26. HLA typing of Epstein-Barr virus transformed lymphoblastoid cell lines (LCL).
    Stinchcombe V; Jones T; Bradley BA
    Tissue Antigens; 1985 Sep; 26(3):161-7. PubMed ID: 2996171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of antiidiotypic antibodies to donor HLA-A2 following blood transfusions in a highly sensitized HLA-A2+ recipient.
    Burlingham WJ; Pan MH; Mason B; Ceman S; Sollinger HW
    Transplantation; 1988 Jun; 45(6):1066-71. PubMed ID: 3289148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of donor cell type on complement-dependent cytotoxicity crossmatch outcome for patients immunized against HLA class-II antigens.
    Arnold ML; Ensminger SM; Doxiadis II; Spriewald BM
    Exp Clin Transplant; 2008 Mar; 6(1):1-6. PubMed ID: 18405238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is flow cytometry crossmatch analysis using sera with different dilutions important for pretransplant analysis? A case report.
    Sağıroğlu T; Tozkır H; Kılıçarslan-Ayna T; Yağcı MA; Sezer A; Carin M
    Transplant Proc; 2012; 44(6):1767-9. PubMed ID: 22841268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flow cytometry crossmatching and primary cadaver kidney graft outcome: relevance of T and B cell targets, historic sera and autologous controls.
    LeFor WM; Ackermann JR; Alveranga DY; Bowers VD; Heinrichs DF; Kahana L; Shires DL; Weinstein SS; Wright CE
    Clin Transplant; 1996 Dec; 10(6 Pt 2):601-6. PubMed ID: 8996750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical importance of choosing the right assay for detection of HLA-specific donor-reactive antibodies.
    Sumitran-Karuppan S
    Transplantation; 1999 Aug; 68(4):502-9. PubMed ID: 10480407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interview with Dr Paul Terasaki.
    Terasaki P
    Am J Transplant; 2003 Sep; 3(9):1047-51. PubMed ID: 12919082
    [No Abstract]   [Full Text] [Related]  

  • 34. HLA antibody screening: comparison of a solid phase enzyme-linked immunoassay with antiglobulin-augmented lymphocytotoxicity.
    Moore SB; Ploeger NA; DeGoey SR
    Transplantation; 1997 Dec; 64(11):1617-20. PubMed ID: 9415570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship of HLA and platelet-reactive antibodies in alloimmunized patients refractory to platelet therapy.
    Brubaker DB; Romine M
    Am J Hematol; 1987 Dec; 26(4):341-52. PubMed ID: 3687931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunologic selection of donors and recipients in renal graft: transplantation antigens ].
    Seignalet J; Mourad G; Mion C
    Nephrologie; 1982; 3(2):73-9. PubMed ID: 6750427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The definition of HLA specificities by cytotoxicity.
    Martin S; Dyer PA
    Transpl Immunol; 1994 Jun; 2(2):108-11. PubMed ID: 7953302
    [No Abstract]   [Full Text] [Related]  

  • 38. Crossmatching with B and T cells and flow cytometry.
    Iwaki Y; Lau M; Cook DJ; Takemoto S; Terasaki PI
    Clin Transpl; 1986; ():277-84. PubMed ID: 3154417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. General insufficiency of the classical CDC-based crossmatch to detect donor-specific anti-HLA antibodies leading to invalid results under recipients' medical treatment or underlying diseases.
    Schlaf G; Mauz-Körholz C; Ott U; Leike S; Altermann W
    Histol Histopathol; 2012 Jan; 27(1):31-8. PubMed ID: 22127594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The incidence of antimonocyte alloantibodies. Evidence that prospective crossmatching is unnecessary.
    O'Connell PJ; McKenzie A; Tait BD; d'Apice AJ
    Transplantation; 1990 Aug; 50(2):261-4. PubMed ID: 2382293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.